Shopping Cart
- Remove All
Your shopping cart is currently empty
CDK12-IN-E9
🥰Excellent
Catalog No. T14915Cas No. 2020052-55-3
CDK12-IN-E9 is a cell cycle protein kinase (CDK) inhibitor with anticancer and antitumor activity that can be used in the study of breast cancer.
CDK12-IN-E9
🥰Excellent
Catalog No. T14915Cas No. 2020052-55-3
CDK12-IN-E9 is a cell cycle protein kinase (CDK) inhibitor with anticancer and antitumor activity that can be used in the study of breast cancer.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $193 | In Stock | |
| 5 mg | $486 | In Stock | |
| 10 mg | $728 | In Stock | |
| 25 mg | $1,352 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $535 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "CDK12-IN-E9"
Abemaciclib
Cited
LY2835219, CDK4/6 dual inhibitor
T23811231929-97-7
Abemaciclib (LY2835219) is a dual inhibitor of CDK4/6 (IC50=2/10 nM) with selectivity and specificity. Abemaciclib has antitumor activity and is used to treat advanced or metastatic breast cancer.
- $48
Size
QTY
CitedSodium Oxamate Cited
SO, Oxamic acid sodium salt, oxamate sodium, Aminooxoacetic acid sodium salt
T19831565-73-1
Sodium Oxamate (Oxamic acid sodium salt) is an LDH inhibitor that specifically inhibits LDHA. Sodium Oxamate has antitumor activity and induces cell cycle arrest and apoptosis.
- $31
Size
QTY
CitedRibociclib Cited
LEE011
T61991211441-98-3
Ribociclib (LEE011) is an orally available, and highly specific CDK4/6 inhibitor (IC50：10/39 nM).
- $36
Size
QTY
CitedCASIN
Pirl1-related Compound 2
T3971425399-05-9
CASIN (Pirl1-related Compound 2) is a specific inhibitor of GTPase Cdc42 (IC50: 2 uM).
- $32
Size
QTY
Dinaciclib Cited
SCH 727965, PS-095760
T1912779353-01-4
Dinaciclib (SCH 727965) is a selective CDK inhibitor targeting CDK1, CDK2, CDK5, and CDK9 (IC50 = 3/1/1/4 nM). It exhibits potential antitumor activity by inhibiting the incorporation of thoracic glycan (dThd) DNA.
- $47
Size
QTY
CitedAbemaciclib methanesulfonate Cited
LY2835219 mesylate, LY2835219 (methanesulfonate), LY2835219, abemaciclib mesylate
T31111231930-82-7
Abemaciclib methanesulfonate (LY2835219) is a specific and effective inhibitor of CDK4(IC50=2 nM) and CDK6(IC50=10 nM).
- $30
Size
QTY
CitedPalbociclib Cited
PD 0332991
T1785571190-30-2
Palbociclib (PD 0332991) is a CDK inhibitor that inhibits CDK4 and CDK6 (IC50=11/16 nM) and is orally active. Palbociclib has anti-tumorigenic activity and has investigational potential for use in ER-positive and HER2-negative breast cancer.
- $48
Size
QTY
CitedPalbociclib monohydrochloride
PD 0332991 hydrochloride, Palbociclib hydrochloride, Palbociclib (PD-0332991) HCl
T6239827022-32-2
Palbociclib monohydrochloride (PD 0332991 hydrochloride) is a selective inhibitor of CDK4/6 (IC50s: 11/16 nM). It exhibits no inhibition against a panel of 36 additional protein kinases.
- $30
Size
QTY
GW 441756
T6052504433-23-2
GW 441756 is a specific Tropomyosin-related kinase A (TrkA) inhibitor with an IC50 value of 2 nM.
- $51
Size
QTY
Ro-3306 Cited
T2356872573-93-8
RO-3306 is a selectivity ATP-competitive CDK1 inhibitor (Ki: 20 nM). The selectivity of RO-3306 for CDK1 is >15-fold higher than a diverse panel of human kinases.
- $32
Size
QTY
CitedRafoxanide
T709322662-39-1
Rafoxanide as a dual CDK4/6 inhibitor for the treatment of skin cancer. Rafoxanide is a salicylanilide used as an anthelmintic. It is used to treat fluke, hookworm and other infestations.
- $54
Size
QTY
Select Batch
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | CDK12-IN-E9 is a cell cycle protein kinase (CDK) inhibitor with anticancer and antitumor activity that can be used in the study of breast cancer. |
| Targets&IC50 | CDK2-CyclinA:932 nM, CDK7-CyclinH-MNAT1:1210 nM, CDK9-CyclinT1:23.9 nM |
| In vitro | CDK12-IN-E9 treatment of Kelly, LAN5, SK-N-BE2, PC-9, NCI-H82, and NCI-H3122 cells after 72 hours of action in the concentration range of 10 nM to 10 μM showed significant antiproliferative activity against THZ1R neuroblastoma and lung cancer cells, with IC50 values ranging from 8 to 40 nM. After 6 hours of action in the concentration range of 0 to 3000 nM, CDK12-IN-E9 treatment of Kelly, PC-9, and NCI-H82 cells induced a dose-dependent decrease in phosphorylated and total RNAPII accompanied by a decrease in MYC and MCL1 expression in THZ1R neuroblastoma and lung cancer models. In addition, CDK12-IN-E9 increased PARP cleavage and elevated the proportion of sub-G1 phase cells in THZ1R lung cancer cells, whereas it was more likely to cause G2/M phase block in neuroblastoma cells after 24 hours of exposure. [1] |
| Molecular Weight | 434.53 |
| Formula | C24H30N6O2 |
| Cas No. | 2020052-55-3 |
| Smiles | C(C)C1=C2N(C(NC3=CC(NC(C=C)=O)=CC=C3)=CC(=N2)N4[C@H](CCO)CCCC4)N=C1 |
| Relative Density. | 1.28 g/cm3 (Predicted) |
Storage & Solubility Information
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 100 mg/mL (230.13 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy CDK12-IN-E9 | purchase CDK12-IN-E9 | CDK12-IN-E9 cost | order CDK12-IN-E9 | CDK12-IN-E9 chemical structure | CDK12-IN-E9 in vitro | CDK12-IN-E9 formula | CDK12-IN-E9 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.